Literature DB >> 2191690

Animal models for intranasal drug delivery studies. A review article.

S Gizurarson1.   

Abstract

The purpose of this review is to introduce the investigators to sources of information and to guiding principles regarding the choice of animal models for experimental and clinical studies on intranasal application studies. It focuses also on the anatomical and physiological variations that can influence the selection of the correct animal model. A topical overview is given for following animal models which are all involved in intranasal drug or vaccine delivery research; dog, guinea pig, hamster, mouse, rabbit (in vivo and in situ), rat (in vivo, in vivo surgical and in situ) and sheep. In the selection of an animal model, both advantages and disadvantages must be considered. Small animals such as guinea pigs, hamsters, mice and rats, are easy to handle and inexpensive, but their nasal cavity is small and therefore preferred for absorption studies and for studying the influence of absorption promoters. Dogs, monkeys, sheep and rabbits are particularly useful in pharmacokinetic and formulation studies.

Entities:  

Mesh:

Year:  1990        PMID: 2191690

Source DB:  PubMed          Journal:  Acta Pharm Nord        ISSN: 1100-1801


  20 in total

1.  The toxicity of microcystin LR in mice following 7 days of inhalation exposure.

Authors:  Janet M Benson; Julie A Hutt; Kathleen Rein; Susan E Boggs; Edward B Barr; Lora E Fleming
Journal:  Toxicon       Date:  2005-05       Impact factor: 3.033

Review 2.  The nasal mucociliary clearance: relevance to nasal drug delivery.

Authors:  N G Schipper; J C Verhoef; F W Merkus
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

3.  Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract.

Authors:  Frederik W van Ginkel; Raymond J Jackson; Naoto Yoshino; Yukari Hagiwara; Daniel J Metzger; Terry D Connell; Hong L Vu; Michael Martin; Kohtaro Fujihashi; Jerry R McGhee
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Nasal insulin delivery with dimethyl-beta-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations.

Authors:  N G Schipper; S G Romeijn; J C Verhoef; F W Merkus
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

5.  An assessment of the central disposition of intranasally administered insulin lispro in the cerebrospinal fluid of healthy volunteers and beagle dogs.

Authors:  Stephen Lowe; Emanuele Sher; Graham Wishart; Kimberley Jackson; Eunice Yuen; Claire Brittain; Siew Chinn Fong; David O Clarke; William H Landschulz
Journal:  Drug Deliv Transl Res       Date:  2017-02       Impact factor: 4.617

6.  Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal, and Intra-Articular.

Authors:  Armaghan Emami; Jeff Tepper; Brian Short; Tony L Yaksh; Alison M Bendele; Thulasi Ramani; Alvaro F Cisternas; Jay H Chang; R Daniel Mellon
Journal:  Int J Toxicol       Date:  2017-12-21       Impact factor: 2.032

Review 7.  Photoacoustic tomography: fundamentals, advances and prospects.

Authors:  Junjie Yao; Lihong V Wang
Journal:  Contrast Media Mol Imaging       Date:  2011 Sep-Oct       Impact factor: 3.161

Review 8.  Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS.

Authors:  Anupam Sarma; Malay K Das
Journal:  Mol Biomed       Date:  2020-12-10

9.  Direct nose-to-brain transfer of morphine after nasal administration to rats.

Authors:  Ulrika Espefält Westin; Emma Boström; Johan Gråsjö; Margareta Hammarlund-Udenaes; Erik Björk
Journal:  Pharm Res       Date:  2006-02-25       Impact factor: 4.200

10.  Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques.

Authors:  M J Stenslik; A Evans; F Pomerleau; R Weeks; P Huettl; E Foreman; J Turchan-Cholewo; A Andersen; W A Cass; Z Zhang; R C Grondin; D M Gash; G A Gerhardt; L H Bradley
Journal:  J Neurosci Methods       Date:  2018-03-31       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.